Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
MELBOURNE, Australia, April 11, 2017 /CNW/ -- Propanc Health Group Corporation (OTCQB:PPCH), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the April 6 presentation from James Nathanielsz, Chief Executive Officer, is now available for on-demand viewing at VirtualInvestorConferences.com.
Propanc Health Group Corporation's presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
Recent Company Highlights:
- Propanc completed the low dose group for its GLP-Compliant 28-day repeat-dose toxicity study for its lead product, PRP. No treatment related effects were observed in the animals in this study.
- Propanc received a notification of allowance for its lead patent application from the U.S. Patent Office. The patent application provides broad coverage for a method of treating a solid tumor through administering a pharmaceutical composition comprising a therapeutically effective amount of trypsinogen and chymotrypsinogen to patients.
To view Propanc's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc's email distribution list, please email PPCH@kcsa.com with "Propanc" in the subject line.
Learn more about the event at www.VirtualInvestorConferences.com.
About Propanc Health Group Corporation Inc
Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. The products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes.
In the near term, the Company intends to target patients with limited remaining therapeutic options for the treatment of solid tumors. In the future, it intends to develop its lead product to treat (i) early stage cancer, (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE Propanc Health Group Corporation
For further information: Propanc Investor Contacts: KCSA Strategic Communications, Philip Carlson / Elizabeth Barker, firstname.lastname@example.org; VirtualInvestorConferences.com, Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, email@example.com, http://www.retailinvestorconferences.com